Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
First Claim
1. A platinum (IV) compound having efficacy for the treatment of a medical condition, the compound comprising the structure shown in formula I or II:
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and/or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane structure and function, and protein modulation. Caveolae, caveolin proteins and lipid rafts are known therapeutic targets for numerous biological functions. Diseases and disorders currently known to be therapeutically targeted through caveolae and/or lipid rafts include diabetes, cancer, cardiovascular diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune disorders.
8 Citations
9 Claims
-
1. A platinum (IV) compound having efficacy for the treatment of a medical condition, the compound comprising the structure shown in formula I or II:
-
2. A method of using a platinum (IV) compound in the manufacture of a medicament for the treatment of an oncological disorder, an immune evasion response, cancer metastasis, cancer or tumor development, cardiovascular disease, multiple sclerosis, muscular dystrophy, rheumatoid arthritis, infectious disease, myelosuppression, diabetes, autoimmune disease, AIDS development, retinitis pigmentosa, asthma, Alzheimers disease, endometriosis, conditions associated with Lyme neuroboreliosis, irritable bowel syndrome, optical diseases, or diabetic retinopathy, the method comprising:
- administering a platinum (IV) compound having a structure shown in formula (I) or (II),
-
3. A method of using a platinum (IV) compound in the manufacture of a medicament for the treatment of an oncological disorder, an immune evasion response, cancer metastasis, cancer or tumor development, cardiovascular disease, multiple sclerosis, muscular dystrophy, rheumatoid arthritis, infectious disease, myelosuppression, diabetes, autoimmune disease, AIDS development, retinitis pigmentosa, asthma, Alzheimers disease, endometriosis, conditions associated with Lyme neuroboreliosis, irritable bowel syndrome, optical diseases, or diabetic retinopathy, the method comprising:
- administering a platinum (IV) compound having a structure shown in formula (I) or (II),
-
4. A method of using a platinum (IV) compound in the manufacture of a medicament for the treatment of an oncological disorder, an immune evasion response, cancer metastasis, cancer or tumor development, cardiovascular disease, multiple sclerosis, muscular dystrophy, rheumatoid arthritis, infectious disease, myelosuppression, diabetes, autoimmune disease, AIDS development, retinitis pigmentosa, asthma, Alzheimers disease, endometriosis, conditions associated with Lyme neuroboreliosis, irritable bowel syndrome, optical diseases, or diabetic retinopathy, the method comprising:
- administering a platinum (IV) compound having a structure shown in formula (I) or (II),
-
5. A method of using a platinum (IV) compound in the manufacture of a medicament for the treatment of an oncological disorder, an immune evasion response, cancer metastasis, cancer or tumor development, cardiovascular disease, multiple sclerosis, muscular dystrophy, rheumatoid arthritis, infectious disease, myelosuppression, diabetes, autoimmune disease, AIDS development, retinitis pigmentosa, asthma, Alzheimers disease, endometriosis, conditions associated with Lyme neuroboreliosis, irritable bowel syndrome, optical diseases, or diabetic retinopathy, the method comprising:
- administering a platinum (IV) compound having a structure shown in formula I or II,
-
6. A method for treating infection of a pathogen in a patient in need thereof, the pathogen selected from a group consisting of a virus, a prion, a viral protein, toxin, and a bacteria, the method comprising administering an effective amount of a platinum (IV) compound to the patient,
the platinum (IV) compound having a structure shown in formula (I) or (II),
-
7. A method for treating infection of a pathogen in a patient in need thereof, the pathogen selected from a group consisting of a virus, a prion, a viral protein, toxin, and a bacteria, the method comprising administering an effective amount of a platinum (IV) compound to the patient,
the platinum (IV) compound having a structure shown in formula (I) or (II),
-
8. A method for treating infection of a lentivirus in a patient in need thereof, the lentivirus selected from a group consisting of FIV, SIV, SHIV, and HIV, the method comprising administering an effective amount of a platinum (IV) compound to the patient,
the platinum (IV) compound having a structure shown in formula (I) or (II),
-
9. A method for treating infection of a lentivirus in a patient in need thereof, the lentivirus selected from a group consisting of FIV, SIV, SHIV, and HIV, the method comprising administering an effective amount of a platinum (IV) compound to the patient,
the platinum (IV) compound having a structure shown in formula I or II,
Specification